Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13154766 | 0.88 | CHRM2 (0.32) | ACHEALDH1A1TSHR | |
| SCHEMBL28514197 | 0.83 | MEN1 (0.42) | ACHEALDH1A1TSHRTP53HIF1A | |
| SCHEMBL29308970 | 0.83 | ABCB11 (0.36) | ACHEALDH1A1TSHRTP53HIF1A | |
| SCHEMBL27880456 | 0.83 | ABCB11 (0.36) | ACHEALDH1A1TSHRTP53HIF1A | |
| SCHEMBL1065814 | 0.83 | MEN1 (0.42) | ACHEALDH1A1TSHRTP53HIF1A | |
| SCHEMBL28512896 | 0.83 | MEN1 (0.42) | ACHEALDH1A1TSHRTP53HIF1A | |
| SCHEMBL29104752 | 0.81 | ACHE (0.32) | ACHEALDH1A1TSHRTP53HIF1A | |
| SCHEMBL28656034 | 0.81 | ACHE (0.32) | ACHEALDH1A1TSHRTP53HIF1A | |
| SCHEMBL25345009 | 0.81 | ACHE (0.32) | ACHEALDH1A1TSHRTP53HIF1A | |
| SCHEMBL31425438 | 0.81 | ACHE (0.32) | ACHEALDH1A1TSHRTP53HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-11-24 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | ACHE 2065/4885ALDH1A1 3743/4885TSHR 3378/4885 |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | ACHE 1789/4885ALDH1A1 3666/4885TSHR 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.